Physician
Ophthalmology
Dr. John M. Dixon, MD
|
|
Give Review
John M. Dixon is an expert in the field of Ophthalmology. He went to University of Alabama School of Medicine. University of Alabama School of Medicine is ranked 37/17 in Research/PrimaryCare. Doctor John M. Dixon, MD is a published doctor. He published 83 publications, including: 'The primary use of endocrine therapies.'
Publications
- Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.
- Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.
- Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.
- Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.
- Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
- An integrated view of aromatase and its inhibition.
- Anti-tumor effects of letrozole.
- Local endocrine effects of aromatase inhibitors within the breast.
- Anastrozole (''Arimidex'') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
- Changes in messenger RNA expression of protein kinase A regulatory subunit ialpha in breast cancer patients treated with tamoxifen.
- Safety issues surrounding the use of aromatase inhibitors in breast cancer.
- Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.
- Letrozole as primary medical therapy for locally advanced and large operable breast cancer.
- A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
- Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer.
- Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience.
- Aromatase inhibitors: cellular and molecular effects.
- Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment.
- Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
- Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
- The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
- Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.
- Regulation of aromatase activity within the breast.
- Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
- The pharmacology of letrozole.
- Antiaromatase agents: preclinical data and neoadjuvant therapy.
- Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies.
- The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
- Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.
- MIB-1 assessments in breast cancers.
- Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.
- Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes.
- Estrone and estradiol metabolism in vivo in human breast cysts.
- The effect of tamoxifen on breast tumour vascularity.
- The primary use of endocrine therapies.
- Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group.
- Reproducibility of microvessel counts in breast cancer specimens.
- Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index.
- Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in breast tumour tissues.
- Clinical importance of intratumoral aromatase.
- Breast cancer risk with cyst type in cystic disease of the breast. Larger study found no association between cyst type and breast cancer.
- Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma.
- Prospective evaluation of prognostic factors in operable breast cancer.
- The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer.
- Classification of human breast cysts according to electrolyte and androgen conjugate composition.
- Risk factors for breast cancer.
- ABC of breast diseases. Prognostic factors.
- P-glycoprotein and resistance to tamoxifen.
- Expression of transforming growth factor beta mRNA isoforms in human breast cancer.
- Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy.
- The H-ras oncogene product p21 and prognosis in human breast cancer.
- Cyclic AMP binding proteins and prognosis in breast cancer.
- Hormonal correlates of apocrine secretion in the breast.
- An analysis of the content and morphology of human breast microcysts.
- Androgen metabolism and apocrine differentiation in human breast cancer.
- Natural history of cystic disease: the importance of cyst type.
- Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity.
- Prognostic significance of oestrogen and progestogen receptor activities in breast cancer.
- The relationship of cyst type to risk factors for breast cancer and the subsequent development of breast cancer in patients with breast cystic disease.
- pH of human breast cyst fluids.
- The morphological basis of human breast cyst populations.
- Mammary duct ectasia.
- Clinical assessment of tumour size in primary breast carcinoma.
- Fine needle aspiration cytology, in relationships to clinical examination and mammography in the diagnosis of a solid breast mass.
- Invasive cribriform carcinoma of the breast.
- Infiltrating lobular carcinoma of the breast.
- Fine needle aspiration of the breast: importance of the operator.
- Fine-needle aspiration of breast cancer. Relationship of clinical factors to cytology results in 689 primary malignancies.
- Long-term survivors after breast cancer.
- Periductal mastitis and duct ectasia: different conditions with different aetiologies.
- Specimen-orientated radiography helps define excision margins of malignant lesions detected by breast screening.
- ABC of breast diseases. Breast cancer.
- Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease.
- Which patients are cured of breast cancer?
- The impact of core-biopsy on pre-operative diagnosis rate of screen-detected breast cancers.
- Factors affecting outcome of patients with impalpable breast cancer detected by breast screening.
- Primary lymphoma of the breast.
- Occult lymph node metastases in patients with ''node negative'' breast carcinoma treated with conservation surgery and axillary node sample and who subsequently develo...
- Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
- Chronic abscess formation following mesh mastopexy: case report.
- A comprehensive approach for evaluating telemedicine-delivered multidisciplinary breast cancer meetings in southern Scotland.
- Wound infection after breast biopsy.
Schools
University of Alabama At Birmingham
Baylor University Med Center Hospital
Emory Affil Hosps
Doctors Specialties
- Ophthalmology
Accepted Insurances
Education
-
Baylor University Medical Center -
University of Alabama School of Medicine
Hospital
-
Phoebe Putney Memorial Hospital, North Campus -
Phoebe Putney Memorial Hospital
Drug Facts
| NPI NUMBER | 1316040413 | |
| NPPES Provider LastName | DIXON | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 36571 | |
| NPPES Provider State | AL | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 25491.0 | |
| Distinct Opioid Count | 9.0 | |
| Opioid Claim Count | 977.0 | |
| Percent Opioid Claims | 3.83 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316040413 |
| Last Name Of The Provider | DIXON |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Micheal B. Minix, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scot A. Wall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph C. Berg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajesh R. Rangaraj, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. El-Roy D. Dixon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amanda E. Matthews, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ram R. Peddada, MD
This Doctor is OpenDoctor Recommended.
|